(Q36520576)

14 August 2017

1 reference

title

Economic models of antiretroviral therapy: searching for the optimal strategy (English)

1 reference

14 August 2017

Fred J Hellinger

1

1 reference

14 August 2017

publication date

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

24

1 reference

14 August 2017

issue

7

1 reference

14 August 2017

page(s)

631-642

1 reference

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200624070-00002

Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200624070-00002

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200624070-00002

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200624070-00002

A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study

21 January 2018

1 reference

12 December 2020

Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001.

1 reference

12 December 2020

Comparisons of hospital care for patients with AIDS and other HIV-related conditions

1 reference

12 December 2020

Costs of HIV medical care in the era of highly active antiretroviral therapy

1 reference

12 December 2020

Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS.

1 reference

12 December 2020

The cost of HIV treatment and care. A global review

1 reference

12 December 2020

HIV antiretroviral treatment: early versus later.

1 reference

12 December 2020

The cost effectiveness of combination antiretroviral therapy for HIV disease.

1 reference

12 December 2020

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

12 December 2020

Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.

1 reference

12 December 2020

Therapeutic drug monitoring in HIV infection: current status and future directions

1 reference

12 December 2020

Cost effectiveness of combination HIV therapy: 3 years later

1 reference

12 December 2020

Efavirenz: a pharmacoeconomic review of its use in HIV infection

1 reference

12 December 2020

Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study

1 reference

12 December 2020

Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study

1 reference

12 December 2020

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

1 reference

12 December 2020

Sex differences in antiretroviral therapy-associated intolerance and adverse events

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

The economic impact of the first 10,000 cases of acquired immunodeficiency syndrome in the United States

1 reference

12 December 2020

Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002.

1 reference

12 December 2020

Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults

1 reference

12 December 2020

Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.

1 reference

12 December 2020

Treatment of antiretroviral-drug-resistant HIV-1 infection

1 reference

12 December 2020

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

12 December 2020

Progression to AIDS slowed even more after the first two years with highly active antiretroviral therapy

1 reference

12 December 2020

Hospital and outpatient health services utilization among HIV-infected patients in care in 1999.

1 reference

12 December 2020

Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy

1 reference

12 December 2020

Markov models in medical decision making: a practical guide.

1 reference

12 December 2020

Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression

1 reference

12 December 2020

Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients

1 reference

12 December 2020

Economic impact of delaying or preventing AIDS in persons with HIV

1 reference

12 December 2020

Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era.

1 reference

12 December 2020

Adverse effects of antiretroviral therapy for HIV infection

1 reference

12 December 2020

Cost-Effectiveness of Earlier Initiation of Antiretroviral Therapy for Uninsured HIV-Infected Adults

1 reference

12 December 2020

Assessing the cost-effectiveness of HAART for adults with HIV in England

1 reference

12 December 2020

Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy

1 reference

12 December 2020

The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001

1 reference

12 December 2020

Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991.

1 reference

12 December 2020

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

12 December 2020

Beyond efficacy: the impact of combination antiretroviral therapy on quality of life

1 reference

12 December 2020

Studying the cost of HIV-related illnesses: reflections on the moving target

1 reference

12 December 2020

International perspectives on antiretroviral resistance. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations

1 reference

12 December 2020

Cost and financing of care for persons with HIV disease: an overview

1 reference

12 December 2020

Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy

1 reference

12 December 2020

Costs associated with combination antiretroviral therapy in HIV-infected patients

1 reference

12 December 2020

Strategies for containing drug costs: implications for a Medicare benefit

1 reference

12 December 2020

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis

1 reference

12 December 2020

Available clinical markers of treatment outcome integrated in mathematical models to guide therapy in HIV infection

1 reference

12 December 2020

The lifetime cost of treating a person with HIV.

1 reference

12 December 2020

Long-term impact of highly active antiretroviral therapy on HIV-related health care costs

1 reference

12 December 2020

The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium.

1 reference

12 December 2020

Combination antiretroviral therapy in HIV infection. An economic perspective

1 reference

12 December 2020

A risk-benefit assessment of HIV protease inhibitors

1 reference

12 December 2020

Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules

1 reference

12 December 2020

Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols.

1 reference

12 December 2020

A Monte Carlo simulation for modelling outcomes of AIDS treatment regimens

1 reference

12 December 2020

Antiretroviral therapy and health care utilization: a study of privately insured men and women with HIV disease

1 reference

12 December 2020

Expanded screening for HIV in the United States--an analysis of cost-effectiveness.

1 reference

12 December 2020

10.2165/00019053-200624070-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

14 August 2017

1006237365

0 references

1 reference